The Economics of Treatment for Infants with Respiratory Distress Syndrome

Abstract

Objectives. To define clinical outcomes and prevailing patterns of care for the initial hospitalization of infants at greatest risk for respiratory distress syndrome (RDS); to estimate direct medical care costs associated with the initial hospitalization; and to introduce and demonstrate a simulation technique for the economic evaluation of health care technologies. Method. Clinical outcomes and usual-care algorithms were determined for infants with RDS in three birthweight categories (500-1,000 g; >1,000- 1,500 g; and >1,500 g) using literature- and expert-panel-based data. The experts were practitioners from major U.S. hospitals who were directly involved in the clinical care of such infants. Using the framework derived from the usual care patterns and outcomes, the authors developed an itemized "micro-costing" economic model to sim ulate the costs associated with the initial hospitalization of a hypothetical RDS patient. The model is computerized and dynamic; unit costs, frequencies, number of days, probabilities and population multipliers are all variable and can be modified on the basis of new information or local conditions. Aggregated unit costs are used to estimate the expected medical costs of treatment per patient. Results. Expected costs of initial hospitalization per uncomplicated surviving infant with RDS were estimated to be $101,867 for 500-1,000 g infants; $64,524 for >1,000-1,500 g infants; and $27,224 for >1,500 g infants. Incremental costs of complications among survivors were esti mated to be $22,155 (500-1,000 g); $11,041 (>1,000-1,500 g); and $2,448 (>1,500 g). Expected costs of initial hospitalization per case (including non-survivors) were $100,603; $72,353; and $28,756, respectively. Conclusions. An itemized model such as the one developed here serves as a benchmark for the economic assessment of treatment costs and utilization. Moreover, it offers a powerful tool for the prospective evaluation of new technologies or procedures designed to reduce the incidence of, severity of, and/or total hospital resource use ascribed to RDS. Key words: respiratory distress syndrome; low birthweight; technology assessment; economics; costs. (Med Decis Making 1998;18:44-51)

Get full access to this article

View all access options for this article.

References

Robertson PA , Sniderman SH , Laros RK Jr, et al Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986 Am J Obstet Gynecol 1992,166 1629-45

Avery ME , Mead J.

Surface properties in relation to atelectasis and hyaline membrane disease

Am J Dis Child 1959, 97.517-23

Jobe AH Pulmonary surfactant therapy. N Engl J Med 1993, 28 861-8

Wegman ME

Annual summary of vital statistics—1991

Pediatrics . 1992,90 835-45

Manicscalco WM , Kendig JW , Shapiro DL

Surfactant replacement therapy impact on hospital charges for premature infants with respiratory distress syndrome

Pediatrics 1989,83 1-6

Mugford M. , Piercy J. , Chalmers I. Cost implications of different approaches to the prevention of respiratory distress syndrome. Arch Dis. Child 1991,66 757-64

Schwartz RM , Luby AM , Scanlon JW , Kellogg RJ

Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1,500 g

N Engl J Med 1994, 3301476-80

Oddone EZ , Samsa G. , Matchar DB Global judgments versus decision-model-facilitated judgments are experts internally consistent? Med Decis Making 1994 ,14 19-26

Fink A. , Kosecoff J. , Chassin M. , Brook RH

Consensus methods. characteristics and guidelines for use

Am J Public Health 1984,74 979-83.

10.

Brook RH , Chassin MR , Fink A. , et al A method for detailed assessment of the appropriateness of medical technologies Int J Technol Assess Health Care 1986,2 53-63

11.

Microsoft Excel 5 0 [computer program] MS-DOS version Redmond, WA Microsoft, 1995

12.

Liechty EA , Donovan E. , Purohit D. , et al Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome Pediatrics 1991,88 19-28

13.

Hoekstra RE , Jackson JC , Myers TF , et al Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics 1991,88 10-18.

14.

Long W. , Corbet A. , Cotton R. , et al A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome The American Exosurf Neonatal Study Group I and the Canadian Exosurf Neonatal Study Group N Engl J Med 1991,325.1696-703

15.

Eisenberg JM

Doctors' decisions and the cost of medical care

Ann Arbor, MI

Health Administration Press Perspectives, 1986.5-27

16.

U S Department of Commerce Table 747 Consumer Price Index by Major Groups 1960-1993 In Statistical Abstracts of the United States, 114th Edition Washington, DC, 1994.

17.

Phibbs CS , Phibbs RH , Wakeley A. , Schlueter MA , Sniderman S. , Tooley WH

Cost effects of surfactant therapy for neonatal respiratory distress syndrome

J Pediatr 1993,123 953-62

18.

National Inpatient Profile for Infant Respiratory Distress Syndrome (ICD—9—CM769), Oct 1992-Sept 1993 [computer printout] HCIA, 1994

19.

Eisenberg JM , Schulman KA , Glick H. , Koffer, H. Pharmacoeconomics economic evaluation of pharmaceuticals. In. Strom B (ed) Pharmacoepidemiology 2nd ed. Chichester, NY John Wiley, 1994 469-93